1260TiP - Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancers in Adolescents and Young Adults (AYA)
Psychosocial Aspects of Cancer
Skin cancers
Supportive and Palliative Care
Presenter Annelies Boekhout
Citation Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377
Authors A.H. Boekhout1, M. Hauptmann2, A.J.M. van den Eertwegh3, G.A.P. Hospers4, J.W.B. de Groot5, M.J.B. Aarts6, E. Kapiteijn7, A.J. Ten Tije8, D. Piersma9, W.H.J. Kruit10, K.P.M. Suijkerbuijk11, F.W.P.J. Berkmortel12, G. Vreugdenhil13, R.H. Koornstra14, E. Fiets15, M. Lees16, K.J.M. Janssen17, L.V. van den Poll-Franse18, C.U. Blank19
  • 1Psychosocial Research And Epidemiology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 2Epidemiology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 3Medical Oncology, VU University Medical Centre, Amsterdam/NL
  • 4Medical Oncology, University Medical Centre Groningen, Groningen/NL
  • 5Medical Oncology, Isala, Zwolle/NL
  • 6Medical Oncology, Maastricht University Medical Centre, Maastricht/NL
  • 7Medical Oncology, Leiden University Medical Centre, Leiden/NL
  • 8Medical Oncology, Amphia hospital, Breda/NL
  • 9Medical Oncology, Medical Spectrum Twente, Enschede/NL
  • 10Medical Oncology, Erasmus University Medical Centre, Rotterdam/NL
  • 11Medical Oncology, University Medical Centre Utrecht, Utrecht/NL
  • 12Medical Oncology, Atrium Medical Centre, Sittard/NL
  • 13Medical Oncology, Maxima Medical Centre, Eindhoven/NL
  • 14Medical Oncology, Radboud Medical Centre, - - Nijmegen/NL
  • 15Medical Oncology, Medical Centre Leeuwarden, Leeuwarden/NL
  • 16Oncology, Bristol-Meyers Squibb, Paris/FR
  • 17Oncology, Bristol-Meyers Squibb, Utrecht/NL
  • 18Psychosocial Research And Epidemiology, Netherlands Cancer Institute, Amsterdam/NL
  • 19Medical Oncology, Netherlands Cancer Institute, Amsterdam/NL



After the introduction of ipilimumab, an anti-CTLA-4 monoclonal antibody, durable, long term survival has become a possibility for a subgroup of advanced melanoma patients. Since ipilimumab is a relatively novel drug there are limited data on the long-term physical, psychological, and social functioning of these patients. This study will evaluate the long-term physical and psychosocial performances and the information needs of advanced melanoma survivors who have been treated with ipilimumab.

Trial design

This is a prospectively enrolling, multicentre cohort study. Objectives: To assess health-related quality of life (HRQoL), anxiety, depression, fatigue, fear of cancer recurrence, sexual health and generic health status in patients with advanced melanoma who have survived at least 2 years after ipilimumab treatment (without subsequent other systemic therapies) as compared with healthy controls, and to describe the melanoma-specific HRQoL, impact of cancer, social functioning and information needs in patients with advanced melanoma who have survived at least 2 years after ipilimumab treatment. Patients and healthy control population: Patients with advanced (stage IV or unresectable stage III) melanoma who survived at least 2 years and were treated with ipilimumab between 2011 and 2015 in 14 hospitals in the Netherlands are included. The patient population consists of 3 treatment groups based on time since ipilimumab treatment: 24 to 

Clinical trial identification

Date of release: November 2016

Legal entity responsible for the study

Netherlands Cancer Institute


Bristol-Myers Squibb


A.H. Boekhout: Employee of Bristol-Myers Squibb. M. Lee, KJM Janssen: Employee of and receiving stock from Bristol-Myers Squibb, during the conduct of the study. All other authors have declared no conflicts of interest.